Cargando…
Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’
Background: Acute myocardial infarction (AMI) remains a major cause of death worldwide. Survivors of AMI are particularly at high risk for additional cardiovascular events. Consequently, a comprehensive approach to secondary prevention is necessary to mitigate the occurrence of downstream complicati...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488329/ https://www.ncbi.nlm.nih.gov/pubmed/37685793 http://dx.doi.org/10.3390/jcm12175726 |
_version_ | 1785103448226660352 |
---|---|
author | Daios, Stylianos Anastasiou, Vasileios Moysidis, Dimitrios V. Didagelos, Matthaios Papazoglou, Andreas S. Stalikas, Nikolaos Zegkos, Thomas Karagiannidis, Efstratios Skoura, Lemonia Kaiafa, Georgia Makedou, Kali Ziakas, Antonios Savopoulos, Christos Kamperidis, Vasileios |
author_facet | Daios, Stylianos Anastasiou, Vasileios Moysidis, Dimitrios V. Didagelos, Matthaios Papazoglou, Andreas S. Stalikas, Nikolaos Zegkos, Thomas Karagiannidis, Efstratios Skoura, Lemonia Kaiafa, Georgia Makedou, Kali Ziakas, Antonios Savopoulos, Christos Kamperidis, Vasileios |
author_sort | Daios, Stylianos |
collection | PubMed |
description | Background: Acute myocardial infarction (AMI) remains a major cause of death worldwide. Survivors of AMI are particularly at high risk for additional cardiovascular events. Consequently, a comprehensive approach to secondary prevention is necessary to mitigate the occurrence of downstream complications. This may be achieved through a multiparametric tailored risk stratification by incorporating clinical, laboratory and echocardiographic parameters. Methods: The ‘‘CLEAR-AMI Study’’ (ClinicalTrials.gov Identifier: NCT05791916) is a non-interventional, prospective study including consecutive patients with AMI without a known history of coronary artery disease. All patients satisfying these inclusion criteria are enrolled in the present study. The rationale of this study is to refine risk stratification by using clinical, laboratory and novel echocardiographic biomarkers. All the patients undergo a comprehensive transthoracic echocardiographic assessment, including strain and myocardial work analysis of the left and right heart chambers, within 48 h of admission after coronary angiography. Their laboratory profile focusing on systemic inflammation is captured during the first 24 h upon admission, and their demographic characteristics, past medical history, and therapeutic management are recorded. The angioplasty details are documented, the non-culprit coronary lesions are archived, and the SYNTAX score is employed to evaluate the complexity of coronary artery disease. A 24-month follow-up period will be recorded for all patients recruited. Conclusion: The ‘‘CLEAR-AMI” study is an ongoing prospective registry endeavoring to refine risk assessment in patients with AMI without a known history of coronary artery disease, by incorporating echocardiographic parameters, biochemical indices, and clinical and coronary characteristics in the acute phase of AMI. |
format | Online Article Text |
id | pubmed-10488329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104883292023-09-09 Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ Daios, Stylianos Anastasiou, Vasileios Moysidis, Dimitrios V. Didagelos, Matthaios Papazoglou, Andreas S. Stalikas, Nikolaos Zegkos, Thomas Karagiannidis, Efstratios Skoura, Lemonia Kaiafa, Georgia Makedou, Kali Ziakas, Antonios Savopoulos, Christos Kamperidis, Vasileios J Clin Med Protocol Background: Acute myocardial infarction (AMI) remains a major cause of death worldwide. Survivors of AMI are particularly at high risk for additional cardiovascular events. Consequently, a comprehensive approach to secondary prevention is necessary to mitigate the occurrence of downstream complications. This may be achieved through a multiparametric tailored risk stratification by incorporating clinical, laboratory and echocardiographic parameters. Methods: The ‘‘CLEAR-AMI Study’’ (ClinicalTrials.gov Identifier: NCT05791916) is a non-interventional, prospective study including consecutive patients with AMI without a known history of coronary artery disease. All patients satisfying these inclusion criteria are enrolled in the present study. The rationale of this study is to refine risk stratification by using clinical, laboratory and novel echocardiographic biomarkers. All the patients undergo a comprehensive transthoracic echocardiographic assessment, including strain and myocardial work analysis of the left and right heart chambers, within 48 h of admission after coronary angiography. Their laboratory profile focusing on systemic inflammation is captured during the first 24 h upon admission, and their demographic characteristics, past medical history, and therapeutic management are recorded. The angioplasty details are documented, the non-culprit coronary lesions are archived, and the SYNTAX score is employed to evaluate the complexity of coronary artery disease. A 24-month follow-up period will be recorded for all patients recruited. Conclusion: The ‘‘CLEAR-AMI” study is an ongoing prospective registry endeavoring to refine risk assessment in patients with AMI without a known history of coronary artery disease, by incorporating echocardiographic parameters, biochemical indices, and clinical and coronary characteristics in the acute phase of AMI. MDPI 2023-09-02 /pmc/articles/PMC10488329/ /pubmed/37685793 http://dx.doi.org/10.3390/jcm12175726 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Protocol Daios, Stylianos Anastasiou, Vasileios Moysidis, Dimitrios V. Didagelos, Matthaios Papazoglou, Andreas S. Stalikas, Nikolaos Zegkos, Thomas Karagiannidis, Efstratios Skoura, Lemonia Kaiafa, Georgia Makedou, Kali Ziakas, Antonios Savopoulos, Christos Kamperidis, Vasileios Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ |
title | Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ |
title_full | Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ |
title_fullStr | Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ |
title_full_unstemmed | Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ |
title_short | Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction—Rationale and Design of the ‘‘CLEAR-AMI Study’’ |
title_sort | prognostic implications of clinical, laboratory and echocardiographic biomarkers in patients with acute myocardial infarction—rationale and design of the ‘‘clear-ami study’’ |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488329/ https://www.ncbi.nlm.nih.gov/pubmed/37685793 http://dx.doi.org/10.3390/jcm12175726 |
work_keys_str_mv | AT daiosstylianos prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT anastasiouvasileios prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT moysidisdimitriosv prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT didagelosmatthaios prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT papazoglouandreass prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT stalikasnikolaos prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT zegkosthomas prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT karagiannidisefstratios prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT skouralemonia prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT kaiafageorgia prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT makedoukali prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT ziakasantonios prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT savopouloschristos prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy AT kamperidisvasileios prognosticimplicationsofclinicallaboratoryandechocardiographicbiomarkersinpatientswithacutemyocardialinfarctionrationaleanddesignoftheclearamistudy |